Tech Pullback vs Biotech Surge as Markets Waver

Opening Recap

Market Pulse: U.S. stocks drifted into the red Friday as profit-taking in tech collided with a biotech rally, leaving the S&P looking shaky.

Key Movers: Broadcom’s blowout AI quarter couldn’t hold as its shares slipped premarket, and FDA nods for Milestone's CARDAMYST™, Innoviva’s Nuzolvence, and Acadia’s Daybue Stix ignited a biotech short squeeze.

Macro & Politics: Wall Street’s mood wavered ahead of any fresh Fed hints, and Hollywood boardrooms heated up with the Warner Bros. takeover proxy fight starring a cast from billionaires to Trump’s son-in-law.

What’s Next: Keep an eye on Monday’s session for further tech profit-taking and reactions to any merger deal whispers.

Market Commentary

Everyone seems fixated on the latest biotech green lights from Milestone, Innoviva and Acadia, but they’re overlooking the ticking liability bomb in the unapproved weight-loss drug craze laid out in “People Are Already Taking This Unapproved New Weight-Loss Drug” (Wired). If congressional hearings or FDA pushback spark a sell-off in that corner, the whole biotech theme park could deflate before traders realize the ride’s over.

Here’s a wrinkle: as traders were bailing on Broadcom’s dip—despite its record AI-driven quarter in “Broadcom Inc (AVGO) Q4 2025 Earnings Call Highlights: Record Revenue and AI Growth Propel … – Yahoo Finance” (Slashdot.org)—the proxy fight at Warner Bros. roped in billionaires and Jared Kushner in “Warner Bros battle draws in billionaires, celebrities and Trump's son-in-law” (ABC News). That battle ties up M&A capital that might otherwise fuel mega-deals in the semiconductor space, keeping valuations capped across sectors.

Action point: step aside from the hype on crowded biotech and tech trades, and scout mispriced dips in names that just took profits. If Broadcom or Lululemon shifts again on any buyout whispers or leadership shake-ups, that’s your cue to pounce before the next momentum wave.